

# Efficacy of Stand-Alone Anterior Lumbar Interbody Fusion With PEEK Cages, BMP-2, and Allografts for Treating Discogenic Low Back Pain: Assessing Clinical and Radiographic Outcomes

Matthew Scott-Young, David Nielsen, Evelyne Rathbone, Sukhman Riar and Miller Gantt

*Int J Spine Surg* 2024, 18 (5) 502-513

doi: <https://doi.org/10.14444/8679>

<https://www.ijssurgery.com/content/18/5/502>

This information is current as of November 8, 2024.

---

**Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at:  
<http://ijssurgery.com/alerts>

# Efficacy of Stand-Alone Anterior Lumbar Interbody Fusion With PEEK Cages, BMP-2, and Allografts for Treating Discogenic Low Back Pain: Assessing Clinical and Radiographic Outcomes

MATTHEW SCOTT-YOUNG, MBBS, FRACS, FA<sub>ORTHA</sub><sup>1,2</sup>; DAVID NIELSEN, MBBS, FRACS, FA<sub>ORTHA</sub><sup>2</sup>; EVELYNE RATHBONE, MSc, CSTAT<sup>1</sup>; SUKHMANN RIAR, BBIOMED Sc<sup>1,2</sup>; AND MILLER GANTT, BSc<sup>3</sup>

<sup>1</sup>Faculty of Health Science and Medicine, Bond University, Gold Coast, Queensland, Australia; <sup>2</sup>Gold Coast Spine, Gold Coast, Queensland, Australia; <sup>3</sup>School of Medicine, Mercer University, Macon, Georgia, USA

## ABSTRACT

**Background:** Chronic low back pain secondary to degenerative disc disease is a significant public health issue worldwide, contributing to substantial health care burdens and patient disability. Anterior lumbar interbody fusion (ALIF) has emerged as a promising surgical solution, offering benefits such as disc height restoration, reduced neural compression, and improved spinal alignment. This study evaluates the efficacy of stand-alone ALIF using polyetheretherketone (PEEK) cages, structural femoral head allografts, and recombinant human bone morphogenetic protein-2 (rhBMP-2) in treating discogenic low back pain caused by degenerative disc disease.

**Methods:** This prospective case series study included 1335 patients who underwent stand-alone ALIF by a single surgeon. The surgical construct involved PEEK cages with structural femoral allograft dowels and rhBMP-2, supplemented by anterior fixation. Patient-reported outcome measures, including the visual analog scale for back and leg pain, the Oswestry Disability Index, the Roland-Morris Disability Questionnaire, and patient satisfaction, were monitored over 12 months.

**Results:** The overall fusion rate was 99.6%, with pseudoarthrosis occurring in 0.2% of patients. Lower fusion rates were observed in patients older than 65 years and those using the Brantigan cage. Significant improvements were seen in visual analog scale for back and leg pain, Oswestry Disability Index, and Roland-Morris Disability Questionnaire scores from baseline, with most scores exceeding the substantial clinical benefit thresholds. More than 85% of patients reported “Excellent” or “Good” outcomes.

**Conclusions:** Stand-alone ALIF, augmented with rhBMP-2 and structural femoral head allografts, can enhance mechanical stability, fusion rates, and radiographic assessment. This integrated approach achieves successful spinal fusion and positive clinical outcomes for patients with refractory discogenic low back pain.

**Clinical Relevance:** Stand-alone ALIF with PEEK cages, structural femoral head allografts, and rhBMP-2 demonstrates high fusion rates and significant clinical improvements in patients with discogenic low back pain. This approach enhances spinal stability and promotes biological healing, making it a reliable and effective surgical option.

**Level of Evidence:** 4.

Lumbar Spine

Keywords: ALIF, PEEK cages, spinal fusion, rhBMP-2, degenerative disc disease

## INTRODUCTION

Chronic low back pain (CLBP) remains a significant local and global health issue, profoundly impacting individuals and health care systems worldwide.<sup>1</sup> The Australian Burden of Disease study highlights back pain as a leading cause of nonfatal burden.<sup>2</sup> With an estimated 3.7 million Australians suffering from chronic back problems, the economic toll exceeds AU\$4.8 billion annually, and this figure is expected to rise.<sup>2</sup> Such data underscore the importance of finding practical solutions for CLBP.<sup>3</sup>

Within the spectrum of CLBP, discogenic origins contribute to neurogenic, biomechanical, and biochemical changes within the intervertebral disc.<sup>4</sup> Progressive degeneration results in loss of disc height and associated neural compression, potentially leading to debilitating radiculopathy.<sup>5</sup> Despite the proliferation of nonsurgical interventions, their efficacy remains contentious, prompting the exploration of surgical options for refractory cases.<sup>6–9</sup>

Conventional spinal fusion is a viable option when conservative measures prove inadequate. However,

debates persist regarding the clinical efficacy of fusion procedures, highlighting the need for a nuanced understanding and optimization of fusion techniques.<sup>10,11</sup> Reliable bony fusion, governed by intricate physiological and biomechanical principles, is central to this effort.<sup>12,13</sup>

The contemporary landscape of spinal fusion is witnessing a surge in innovation, particularly with interbody fusion (IBF) cages. Polyetheretherketone (PEEK), known for its biomechanical compatibility with human bone, has emerged as a preferred biomaterial for IBF. Despite its mechanical advantages, concerns regarding osseointegration have led to advancements in surface modifications to enhance bone-implant interactions.<sup>14–16</sup>

Amid these advancements, anterior lumbar interbody fusion (ALIF) is a technique that restores disc height and lordosis, reducing back and leg symptoms.<sup>17</sup> Moreover, it plays a crucial role in protecting the dynamic stabilizers and the erector spinae muscles. By combining meticulous surgical technique with Giannoudis's Diamond Concept principles,<sup>18</sup> ALIF with PEEK cages, supplementary fixation, structural femoral head allograft, and recombinant human bone morphogenetic protein-2 (rhBMP-2) offers an integrated approach to successful fusion.<sup>19–23</sup> This approach sets a paradigm for addressing the complexities of CLBP with precision and efficacy.<sup>24</sup> PEEK cages provide essential structural support, BMP-2 stimulates bone growth, and allografts scaffold new bone development.<sup>25,26</sup>

The present study evaluates the effectiveness of stand-alone ALIF in managing discogenic low back pain. The study focuses on the benefits of this approach, particularly its impact on spinal stability, biological healing, pain relief, and functional improvement. It posits that integrating standalone ALIF with PEEK cages, structural femoral head allografts, and rhBMP-2 enhances spinal stability and promotes reliable, consistent biological healing.

## METHODS


This prospective study involved 1335 patients who underwent anterior lumbar reconstruction surgery performed by a single surgeon at a single institution with a follow-up period of 12 months. The ALIF surgical construct utilized PEEK cages with structural femoral allograft dowels and rhBMP-2, supplemented by anterior fixation (either a plate-screw construct or integrated screws). Surgical access was gained through a midline rectus split, followed by a left or right retroperitoneal approach. When approaching higher levels, a left retroperitoneal approach was used.

Critical outcomes assessed were ALIF fusion rates and patient-reported outcome measures (PROMs). Pain was measured using the visual analog scale for the back (VAS-B) and leg (VAS-L). Disability was assessed using the Oswestry Disability Index (ODI) and the Roland-Morris Disability Questionnaire (RMDQ). Patient satisfaction was evaluated using a 4-point scale: poor, satisfactory, good, and excellent.<sup>27,28</sup>

Fusion outcomes were categorized into 4 groups: first, “fused (CT + XR),” confirmed by fine-cut computed tomography (CT) and erect flexion-extension radiography; second, “fused (XR),” confirmed by erect flexion-extension radiography only; third, “pseudoarthrosis,” indicating no fusion; and finally, “unavailable.” The change in imaging modality throughout this study—from dynamic radiography alone to the inclusion of fine-cut CT—reflects evolving recommendations in spinal literature regarding the gold standard for fusion assessment.<sup>29</sup> The criteria for fusion focused on the presence of a continuous bony bridge across the intervertebral space, ensuring no gaps or lucency at the bone-graft interface (Figure 1). Additionally, the absence of motion on flexion-extension x-ray images and the integrity of surgical hardware, such as no signs of screw loosening or plate migration, were evaluated to confirm successful fusion.<sup>30</sup>

Subgroup analyses were conducted based on several factors, including ALIF levels, age groups, review types, cage types, and ALIF groups (Figure 2). Patients were divided into 2 ALIF groups based on surgical levels: “higher” for L2-3 and L3-4 and “lower” for L4-5, L5-S1, and S1-2. Review types were divided into 2 groups: the “chart” (medical record) group (2005–2008), which relied on clinical notes, radiology reports, and an internal photo library, and the “PACS” group (2009–2019), which used picture archiving and communication system (PACS) images for direct review of complete images to assess fusion.

Surgical hardware was classified into 3 groups based on the type of cage used: “Brantigan” (2005–2009), a PEEK cage with supplementary plate-screw anterior fixation; “STALIF” (2010–2013), a PEEK cage with integrated screws; and “Australis” (2014–2019), a PEEK cage with expanded options for height and lordosis, supplemented with plate-screw anterior fixation. Each standalone cage was packed with a structural femoral head allograft impregnated and wrapped in an absorbable collagen sponge containing a high concentration of rhBMP-2 (Figure 2). No supplemental pedicle screw fixation was applied.



**Figure 1.** Dynamic x-ray images showing stability across the anterior lumbar interbody fusion construct in flexion (A) and extension (B). Fine-cut computed tomography images showing confluent bridging bone assessed on sagittal (C) and coronal (D) sequences.


Each patient was treated as a single unit of analysis, resulting in a robust sample size of 1335. This method was chosen to avoid duplicative counting, which would have occurred if the sample had been split into separate levels ( $n = 1614$ ).

### Statistical Analysis

Statistical analysis was performed using R statistical software (version 4.0.2). Descriptive statistics, including mean and SD, were obtained for normally

distributed continuous variables, while counts and percentages were used for categorical variables. Exploratory analyses of overall fusion data and fusion rates at 6 and 12 months were conducted using the  $\chi^2$  test, with a significance level of 2.05. Age groups, review types, cage types, and ALIF groups assessed differences in proportions.

PROMs were summarized using the median and interquartile range at various time points. Changes in VAS-L and VAS-B scores from baseline were estimated



**Figure 2.** Preparation of anterior lumbar interbody fusion surgical constructs. (A) Hole drilled through femoral head allograft and recombinant human bone morphogenetic protein-2 (rhBMP-2) sponge packed inside. (B) The allograft wrapped in rhBMP-2 sponge. (C) Construct press-fitted inside the polyetheretherketone cage. (D) Cage, allograft, and rhBMP-2.

using the Hodges-Lehmann estimator. The 95% confidence intervals and *P* values were derived from a non-parametric sign test. Changes from baseline in ODI and RMDQ were assessed using paired *t* tests, with mean differences and 95% CIs reported. A Bonferroni correction was applied, with *P* values less than 0.017 considered statistically significant for each PROM.<sup>28</sup>

Graphical representations of change scores, along with 95% CIs and the minimum clinically important difference<sup>31,32</sup> for VAS-B (12 points), VAS-L (16 points), ODI (10 points), and RMDQ (5 points), were plotted. Substantial clinical benefit (SCB)<sup>33</sup> reference lines were included at 25 points for VAS and 18.8 points for ODI.

The effect of subgroups on change scores was examined using mixed-effects regression, with patients as a random factor and time (in months) as the repeated measures factor. Post-hoc comparisons were conducted with Bonferroni correction for multiplicity, with a significance level of 0.05. This approach is robust to slight to moderate residual skewness and can handle missing data.

## RESULTS

Table 1 summarizes the demographic characteristics of the 1335 patients. The mean age at the time of surgery was 48.5 years, with most patients (70.9%) in the 40 to 65 age group. Most surgeries were reviewed using PACS images (80.3%) and utilized Australis cages (43.4%). Many cases involved single-level ALIF constructs (80.3%), typically only involving lower levels (96%), with L5 to S1 being the most common level fused (95.4%).

### Fusion Rates

Regarding fusion rates (Table 2), overall confirmed fusion rates were high, with 1329 patients (99.6%) achieving fusion after surgery. The confirmed pseudoarthrosis rate was 0.2% (3 patients), and 3 patients did not have radiological information available for review.

Most fusions (92.4%) were confirmed by 6 months. Interestingly, of the 1235 patients who had confirmed fusion by the preassigned 6-month postoperative period, 43 patients mistakenly obtained their CT image earlier than expected at 3 months postoperatively but still demonstrated confirmed mature fusion.

A small number of patients (*n* = 7) had confirmation of their fusion after the 12-month postoperative period. The reasons identified were (1) compliance issues with radiological follow-up (4 patients in total:

**Table 1.** Demographic characteristics of study participants.

Characteristic	<i>n</i> (%)
Age at time of surgery, y, mean (SD)	48.5 (11.4)
Age group	
<40 y	303 (22.7)
40–65 y	946 (70.9)
>65 y	86 (6.4)
Review type	
Chart (2005–2008)	263 (19.7)
PACS image (2009–2019)	1072 (80.3)
Cage type	
Brantigan (2005–2009)	374 (28.0)
STALIF (2010–2013)	381 (28.5)
Australis (2014–2019)	580 (43.4)
ALIF level	1614 (100.0)
L2–L3	3 (0.2)
L3–L4	52 (3.9)
L4–L5	279 (20.9)
L5–S1	1273 (95.4)
S1–S2	7 (0.5)
ALIF group	
Higher (cases with L2–L3 and L3–L4)	54 (4.0)
Lower (cases with L4–L5 and lower)	1281 (96.0)
Single level	1072 (80.3)
L2–L3	1 (0.1)
L3–L4	4 (0.3)
L4–L5	46 (3.4)
L5–S1	1018 (76.3)
S1–S2	3 (0.2)
2-Level	247 (18.5)
L3–L4/L4–L5	7 (0.5)
L3–L4/L5–S1	26 (1.9)
L4–L5/L5–S1	210 (15.7)
L5–S1/S1–S2	4 (0.3)
3-Level	16 (1.2)
L2–L3/L3–L4/L4–L5	1 (0.1)
L2–L3/L4–L5/L5–S1	1 (0.1)
L3–L4/L4–L5/L5–S1	14 (1.0)

Abbreviations: ALIF, anterior lumbar interbody fusion; PACS, picture archiving and communication system.

Note: Data presented as *n* (%) unless otherwise noted.

2 patients confirmed at 24 months, 1 patient confirmed at 36 months, and 1 patient confirmed at 60 months); (2) documentation issues in medical record notes and radiology reports in the Chart Review Type group (2 patients, confirmed at 24 months); (3) a combination of both compliance and documentation issues (1 patient from the Chart Review Type group, who had confirmed fusion at 48 months).

Figure 3 displays fusion rates at 6 and 12 months by age group, review type, cage type, and ALIF group. Notably, patients older than 65 years showed a lower fusion rate (*n* = 1 of 4; 75% at 12 months) than younger age groups. However, no significant association between age group and fusion rates was found.

### Association Between Age Group and Fusion

There was no significant association between age group and fusion rates (Figure 3A), with confirmed fusion achieved in 99.7% for those younger than 40 years, 99.6% for those aged 40 to 65 years, and 98.8%

**Table 2.** Fusion rates for 1335 surgery patients.

Fusion	Overall (n = 1335)	Months After Surgery			
		6 (n = 1235)	12 (n = 90)	>12 (n = 7)	NA (n = 3)
Fused (CT + XR)	1313 (98.4)	1225 (91.8)	83 (6.2)	5 (0.4)	-
Fused (XR)	16 (1.2)	8 (0.6)	6 (0.4)	2 (0.1)	-
Pseudoarthrosis	3 (0.2)	2 (0.1)	1 (0.1)	-	-
Unavailable	3 (0.2)	-	-	-	3 (0.2)

Abbreviations: CT, computed tomography; NA, not applicable; XR, x-ray imaging.  
 Note: Data are presented as n (%). Percentages for cells under “months after surgery” are calculated from the total sample size.

for those aged older than 65 years. Comparison through  $\chi^2$  analysis was performed: < 40 years vs 40 to 65 years ( $\chi^2 = 0.1$ , difference = 0.1 [95% CI – 1.4, 0.8],  $P = 0.80$ ), 40 to 65 years vs >65 ( $\chi^2 = 1.1$ , difference = 0.8 [95% CI – 0.4, 6.0],  $P = 0.30$ ), and <40 years vs >65 ( $\chi^2 = 1.1$ , difference = 0.9 [95% CI – 0.9, 6.1],  $P = 0.30$ ).


**Association Between Review Type and Fusion**

Confirmed fusion rates were not significantly different overall between the Chart (98.9%) and PACS image (99.7%) review groups ( $\chi^2 = 3.0$ , difference = 0.8 [95% CI – 0.1, 2.9],  $P = 0.085$ ; Figure 3B). However, the

proportion of patients for whom fusion was confirmed through CT and XR was 4.1% higher in the PACS image group (99.2%) than in the Chart group (95.1%;  $\chi^2 = 22.4$ , difference = 4.1 [95% CI – 1.9, 7.4],  $P < 0.001$ ). Conversely, the proportion of patients for whom fusion was confirmed through XR was only 3.2% higher in the Chart group (3.8%) than in the PACS image group (0.6%;  $\chi^2 = 17.8$ , difference = 3.2 [95% CI – 1.4, 6.3],  $P < 0.001$ ). No significant differences were noted between review types at 6 or 12 months after surgery.

**Association Between Cage Type and Fusion**

Regarding cage type (Figure 3C), no confirmed instances of pseudoarthrosis were observed in either the Brantigan (traditional cage-plate-screw construct) or STALIF cages (integrated screw-cage construct). However, radiological outcomes were not obtainable for 2 patients in the Brantigan group due to the unavailability of PACS imaging at the time, and comments on confirmed radiological reviews were not explicitly defined during the medical record review process.



**Figure 3.** Fusion rates at 6 and 12 months by age, review, cage, and anterior lumbar interbody fusion (ALIF) groups. (A) \*Lower fusion rate of (n = 1 of 4) 75% at 12 months for the >65 groups compared with other groups: <40 ( $P < 0.001$ ) and 40–65 ( $P = 0.014$ ). (B) No significant difference was detected between reviews. (C) \*Higher fusion rates (CT + XR) were obtained with STALIF (99.7%) and Australis (99.6%) cages at 6 months than with Brantigan (97.7%). There is no significant difference in overall fusion rates between cage types. (D) \*At 12 months, all patients in the Lower ALIF group achieved fusion compared with (n = 1 of 6) 83.3% in the higher group ( $P < 0.001$ ). CT, computed tomography; PACS, picture archiving and communication system; XR, x-ray imaging.



**Figure 4.** Fusion rates in spine surgery patients ( $n = 1335$ ) were higher than 95% in all available cases, except for the L3–L4/L4–L5/L5–S1 anterior lumbar interbody fusion (ALIF) combination at 12 months, where two-thirds of the group achieved fusion ( $n = 1$  of 3, 66.7%). However, it is noteworthy that all 11 cases with the same combination achieved fusion at 6 months. There were 2 cases of pseudoarthrosis at single levels (L4–L5 and L5–S1) at 6 months (the latter is hard to detect on the graph due to the high percentage of patients achieving fusion). The third case occurred at 12 months in a 3-level ALIF.

In the Australis cage group (contemporary cage-plate-screw construct), 3 patients (0.5%) had confirmed pseudoarthrosis. The  $\chi^2$  analysis revealed no statistically significant difference in confirmed fusion rates between the Brantigan and STALIF cages ( $\chi^2 = 3.1$ , difference = 0.8 [95% CI – 0.3, 2.3],  $P = 0.08$ ), Brantigan vs Australis ( $\chi^2 = 0.3$ , difference = 0.3 [95% CI – 0.8, 1.9],  $P = 0.56$ ), and STALIF vs Australis ( $\chi^2 = 1.9$ , difference = 0.5 [95% CI – 0.6, 1.5],  $P = 0.17$ ).

#### Association Between ALIF Group and Fusion

Two instances of pseudoarthrosis were reported in the lower ALIF group and 1 in the higher ALIF group (Figure 3D). The  $\chi^2$  analysis found no significant difference between these ALIF groups ( $\chi^2 = 2.5$ , difference = 1.5 [95% CI – 0.1, 9.5],  $P = 0.11$ ).

#### Association Between ALIF Construct Combinations and Fusion

Figure 4 illustrates the fusion rates for single-, 2-, and 3-level ALIF categories at various postoperative time points. In the single-level ALIF construct, 2 patients experienced pseudoarthrosis (1 at L4 and another at L5–S1). Additionally, 1 patient had pseudoarthrosis in a multilevel ALIF construct involving L3 to L4, L4 to L5, and L5 to S1.

#### Clinical Outcomes

Table 3 and Table 4 show pain and disability PROMs for the entire cohort. All differences from baseline were statistically significant ( $P < 0.001$ ). The changes from baseline scores were also clinically substantial for all outcomes (Figures 5 and 6). Most scores were above the SCB threshold, except for VAS-L at 3 months. Concerning patient satisfaction, more than 85% reported “excellent” or “good” at all collected time points (Figure 7).

**Table 3.** VAS back and leg pain outcomes over 12 months in 1335 surgery patients.

Months Postsurgery	VAS Outcome			Change From Baseline			P <sup>b</sup>
	n	Median	IQR	n	Median Difference <sup>a</sup>	95% CI	
Back Pain							
0 (baseline)	1058	72.0	56.3–83.0				
3	1274	17.0	5.3–38.0	1019	46.0	45.0–50.0	<0.001
6	1227	11.0	3.0–26.0	975	54.0	52.0–57.0	<0.001
12	1120	9.0	2.0–23.0	915	56.0	53.0–58.0	<0.001
Leg Pain							
0 (baseline)	1049	43.0	9.0–72.0				
3	1274	9.0	0.0–30.0	1010	18.0	15.0–23.0	<0.001
6	1225	2.0	0.0–15.0	965	26.0	22.0–30.0	<0.001
12	1116	2.0	0.0–13.0	900	28.0	23.0–33.0	<0.001

Abbreviations: IQR, interquartile range; VAS, visual analog scale (0 = no pain to 100 = worst pain).

<sup>a</sup>A positive median difference indicates an improvement or reduction in pain score.

<sup>b</sup>All differences from baseline were statistically significant.

### Effect of Time, Age, Cage, and ALIF Group on Clinical Outcomes

Linear mixed-effects regression was used to analyze the effect of time (in months) and key subgroups (age, cage type, and ALIF group) on change scores, adjusting for baseline scores. The review type was excluded from multivariable models due to its strong correlation with cage type and its relevance only to the Brantigan cage. Results in Tables 5 and 6 indicate some statistically significant differences; however, the mean differences in improvement between groups at 3 to 12 months after surgery were generally minor and not clinically significant.

Improvements in VAS-B scores were consistent across age groups. Younger patients demonstrated statistically significantly greater improvements in VAS-L scores compared with older patients, suggesting better neurological recovery potential for radiculopathy in younger individuals. Patients younger than 40 years also showed more significant improvements in disability compared with those aged 40 to 60 years, likely due

to better recovery potential and less extensive degenerative disease. However, those older than 65 years had statistically comparable improvements in disability to both younger age groups (<40 years and 40–60 years). This may be attributed to differing functional demands associated with periretirement lifestyle changes.

## DISCUSSION

This study explored the associations between age, review type, cage type, ALIF group, and fusion rates with standalone ALIF. Fusion rates between the medical record review group (98.9%) and the PACS image review group (99.7%) were similar, though the PACS group had a higher proportion of confirmed fusion through CT and x-ray imaging. Different cage types exhibited varying fusion rates, with the Brantigan cage showing slightly lower fusion rates than the STALIF and Australis cages. In the age subgroup analysis, 12 months postsurgery, patients older than 65 years had lower fusion rates 75% (*n* = 1 of 4) compared with those

**Table 4.** ODI and RMDQ disability outcomes over 12 months in 1335 surgery patients.


Months Postsurgery	Disability Outcome			Change From Baseline			P <sup>b</sup>
	n	Median	IQR	n	Mean Difference <sup>a</sup>	95% CI	
ODI							
0 (baseline)	1058	42.0	32.0–53.0				
3	1262	18.0	8.0–29.8	1011	23.4	22.2–24.5	<0.001
6	1222	10.0	2.0–20.0	972	29.8	28.8–30.9	<0.001
12	1115	8.0	0.0–20.0	910	30.9	29.8–32.1	<0.001
RMDQ							
0 (baseline)	1059	16.0	12.0–19.0				
3	1266	5.0	2.0–9.0	1012	9.2	8.8–9.7	<0.001
6	1221	2.0	0.0–5.0	970	11.6	11.2–12.0	<0.001
12	1115	1.0	0.0–4.0	908	12.2	11.8–12.6	<0.001

Abbreviations: IQR, interquartile range; ODI, Oswestry Disability Index (0 = no disability to 100 = worst disability); RMDQ, Roland-Morris Disability Questionnaire (0 = no disability to 24 = worst disability).

<sup>a</sup>A positive mean difference indicates an improvement or reduction in disability score.

<sup>b</sup>All differences from baseline were statistically significant.






**Figure 5.** Median differences from baseline and 95% confidence interval for visual analog scale (VAS) back and leg pain scores over 12 months after surgery. All median change scores were above the minimal clinically important difference (MCID), and most median scores were above the substantial clinical benefit (SCB).


younger than 40 years (100%) and those aged 40 to 65 years (100%). At 12 months, the lower ALIF group achieved a 100% fusion rate, compared with 83.3% ( $n = 1$  of 6) in the higher ALIF group, with a significant difference noted ( $P < 0.001$ ).

Additionally, PROMs for the entire cohort indicated that all baseline differences were statistically significant ( $P < 0.001$ ). Changes from baseline scores were also clinically

significant for all outcomes, with most scores surpassing the SCB threshold,<sup>33,34</sup> except for VAS-L at 3 months. These findings highlight age, imaging review methods, and cage types as important factors influencing fusion outcomes, with notable improvements from baseline clinical measures. The combination of structural allograft, BMP-2, and Giannoudis's Diamond Concept principles may have contributed significantly to this study's high fusion rate and clinical success.



**Figure 6.** Mean differences from baseline and 95% confidence interval for Oswestry Disability Index (ODI) and Roland-Morris Disability Questionnaire (RMDQ) disability scores over 12 months after surgery. All mean change scores were above the minimal clinically important difference (MCID) for both measures and above the substantial clinical benefit (SCB) for ODI. No SCB reference was available for RMDQ.



**Figure 7.** Patient satisfaction levels within 12 months after surgery rated as poor (1), satisfactory (2), good (3), or excellent (4).

Standalone ALIF for the treatment of recalcitrant discogenic low back pain secondary to degenerative disc disease offers significant benefits supported by clinical evidence.<sup>35-37</sup> Discogenic pain is often associated with radiculopathy.<sup>38</sup> The anterior retroperitoneal or transperitoneal approach provides direct access to the disc space, allowing for thorough disc removal and endplate preparation, which creates a more extensive surface

area between the bony endplate and the cage and graft. ALIF allows direct and indirect neural decompression, restores disc height and lumbar lordosis, improves spinal alignment in the coronal and sagittal planes, and reduces pain.<sup>39,40</sup> By avoiding the posterior approach, ALIF minimizes the risk of damage to the paraspinal muscles, posterior ligaments, and neural elements. The ability to place larger implants improves load distribution and

**Table 5.** Results of the between-groups post-hoc comparisons of the change in pain outcomes after controlling for baseline scores in a multivariable mixed-effects regression model.

Comparison	Estimated Difference <sup>a</sup>	95% CI		P	
		Lower	Upper		
<b>Change in VAS back pain<sup>b</sup></b>					
3 mo	6 mo	5.30	3.92	6.68	<0.001 <sup>c</sup>
6 mo	12 mo	1.47	0.04	2.90	0.13
3 mo	12 mo	6.77	5.36	8.18	<0.001 <sup>c</sup>
<40 y	40-65 y	2.37	-0.30	5.04	0.25
40-65 y	>65 y	1.45	-3.02	5.92	>0.99
<40 y	>65 y	0.92	-3.97	5.80	>0.99
Brantigan	STALIF	2.51	-0.19	5.20	0.21
STALIF	Australis	3.01	0.25	5.77	0.10
Brantigan	Australis	5.51	2.84	8.19	<0.001 <sup>c</sup>
Higher ALIF	Lower ALIF	7.49	1.83	13.14	0.010 <sup>c</sup>
<b>Change in VAS leg pain<sup>a</sup></b>					
3 mo	6 mo	7.86	6.31	9.41	<0.001 <sup>c</sup>
6 mo	12 mo	0.64	-0.97	2.25	>0.99
3 mo	12 mo	8.50	6.91	10.09	<0.001 <sup>c</sup>
<40 y	40-65 y	4.36	1.92	6.80	0.001 <sup>c</sup>
40-65 y	>65 y	6.60	2.33	10.87	0.007 <sup>c</sup>
<40 y	>65 y	10.96	6.34	15.58	<0.001 <sup>c</sup>
Brantigan	STALIF	2.26	-0.27	4.79	0.24
STALIF	Australis	1.89	-0.66	4.44	0.44
Brantigan	Australis	4.15	1.63	6.68	0.004 <sup>c</sup>
Higher ALIF	Lower ALIF	0.49	-4.72	5.70	0.85

Abbreviations: ALIF, anterior lumbar interbody fusion; VAS, visual analog scale.

<sup>a</sup>The estimated difference is the more significant improvement experienced by the category in bold text for each pairwise comparison. None of the estimated differences between groups were clinically significant.

<sup>b</sup>The estimated mean improvement at 3 months postsurgery for a <40-year-old patient with mean baseline, Brantigan cage, and higher ALIF were 44.7 for back pain and 26.6 for leg pain.

<sup>c</sup>Statistically significant difference  $P < 0.05$ .

**Table 6.** Results of the between-groups post-hoc comparisons of the change in disability outcomes after controlling for baseline scores in a multivariable mixed-effects regression model.

Comparison	Estimated Difference <sup>a</sup>	95% CI		P	
		Lower	Upper		
<b>Change in ODI<sup>b</sup></b>					
3 mo	6 mo	6.46	5.72	7.21	<0.001 <sup>c</sup>
6 mo	12 mo	0.90	0.12	1.67	0.07
3 mo	12 mo	7.36	6.60	8.12	<0.001 <sup>c</sup>
<40 y	40–65 y	2.88	1.12	4.63	0.004 <sup>c</sup>
40–65 y	>65 y	0.37	-2.55	3.29	>0.99
<40 y	>65 y	3.25	0.05	6.44	0.14
Brantigan	STALIF	0.11	-1.67	1.88	>0.99
STALIF	Australis	1.86	0.04	3.68	0.14
Brantigan	Australis	1.97	0.22	3.72	0.08
Higher ALIF	Lower ALIF	5.74	2.01	9.46	0.003 <sup>c</sup>
<b>Change in RMDQ<sup>b</sup></b>					
3 mo	6 mo	2.37	2.10	2.64	<0.001 <sup>c</sup>
6 mo	12 mo	0.49	0.21	0.77	0.002 <sup>c</sup>
3 mo	12 mo	2.86	2.58	3.14	<0.001 <sup>c</sup>
<40 y	40–65 y	0.80	0.19	1.42	0.030 <sup>c</sup>
40–65 y	>65 y	0.42	-0.60	1.44	>0.99
<40 y	>65 y	1.22	0.11	2.34	0.10
Brantigan	STALIF	0.15	-0.47	0.77	>0.99
STALIF	Australis	0.93	0.29	1.56	0.013 <sup>c</sup>
Brantigan	Australis	1.08	0.47	1.69	0.002 <sup>c</sup>
Higher ALIF	Lower ALIF	2.61	1.32	3.91	<0.001 <sup>c</sup>

Abbreviations: ALIF, anterior lumbar interbody fusion; ODI, Oswestry Disability Index; RMDQ, Roland-Morris Disability Questionnaire.

<sup>a</sup>The estimated difference is the more significant improvement experienced by the category in bold text for each pairwise comparison. None of the estimated differences between groups were clinically significant.

<sup>b</sup>The estimated mean improvement at 3 months postsurgery for a <40-year-old patient with mean baseline, Brantigan cage, and higher ALIF were 25.5 for ODI and 9.8 for RMDQ.

<sup>c</sup>Statistically significant difference  $P < 0.05$ .

fusion rates, and the anterior approach often results in less blood loss.<sup>17</sup>

Burkus et al<sup>41</sup> investigated Infuse Bone Grafts in single-level ALIF surgeries with threaded cortical allografts. The results showed promising outcomes, including high fusion rates and improved clinical measures, with no reported adverse events related to infuse bone grafts.<sup>41</sup> These findings suggest the efficacy and safety of infuse bone graft in facilitating fusion and improving outcomes in this surgical context. Malham et al<sup>19</sup> evaluated the use of rhBMP-2 in ALIF procedures with PEEK cages and separate anterior titanium plates. Significant clinical improvements were noted: back pain was reduced by 57.2%, leg pain by 61.8%, and the ODI improved by 54.3%. Additionally, SF-36 scores showed a 41.7% improvement in the physical component summary and a 21.3% improvement in the mental component summary. The study achieved a solid IBF rate of 96.9% at 12 months. Overall, using rhBMP-2 with PEEK cages and anterior titanium plates in ALIF resulted in high fusion rates and significant clinical improvements with a low complication rate.<sup>19</sup>

Faundez et al<sup>20</sup> systematically reviewed clinical data on adverse events linked to the use of rhBMP-2 in ALIF. They found no significant increase in adverse events when rhBMP-2 was used according to Food and Drug Administration guidelines for one-level ALIF with an LT-CAGE Lumbar Tapered Fusion Device.<sup>20</sup> Two additional randomized controlled trials reported transient bone remodeling without adverse clinical outcomes. The study concluded

that rhBMP-2 is safe and effective in ALIF surgeries when used according to U.S. Food and Drug Administration guidelines, with low complication rates and outcomes comparable or superior to traditional bone grafts.<sup>22,23</sup>

PEEK or carbon fiber-reinforced PEEK cages in ALIF procedures offer significant biomechanical stability. PEEK promotes fusion due to its favorable biomechanical properties and modulus of elasticity, which closely resembles human bone. Incorporating rhBMP-2 and structural allografts within these cages further supports bone healing and fusion, resulting in high fusion rates and reliable radiographic detection.<sup>42</sup> PEEK's mechanical strength, radiolucency, and biocompatibility make it an ideal biomaterial for ALIF surgeries to facilitate successful IBF.<sup>43</sup>

This study's limitations include evolving fusion assessment methodologies, particularly in the pre-PACS era when dynamic x-ray imaging was the accepted standard before adopting postoperative CT evaluation. Although the large sample size is a strength, pseudoarthrosis's small relative effect size makes it challenging to generalize risk factors for nonunion. The study focused exclusively on standalone ALIF constructs, without comparisons to other IBF approaches or circumferential fusion techniques. By tracking PROMs over time, this case series sheds light on the effectiveness of treatments from the patient's perspective, offering insights into changes in symptoms, quality of life, and functionality. Despite being limited by the lack of a

control group and potential biases, this large case series remains a valuable tool for understanding real-world outcomes, supporting clinical decision-making, and informing future research.

## CONCLUSION

In conclusion, standalone ALIF, particularly when augmented with rhBMP-2 and structural femoral head allografts, provides substantial benefits regarding mechanical stability, higher fusion rates, and clear radiographic assessment. Standalone ALIF is a reliable and effective option for patients requiring lumbar fusion. However, further studies on device design, material properties, and biological enhancements are essential for improving spinal fusion success and achieving positive clinical outcomes.

## REFERENCES

1. Solumsmoen S, Poulsen G, Kjellberg J, Melbye M, Munch TN. The impact of specialised treatment of low back pain on health care costs and productivity in a nationwide cohort. *eClin Med*. 2022;43:101247. doi:10.1016/j.eclinm.2021.101247
2. Walker BF, Muller R, Grant WD. Low back pain in Australian adults; the economic burden. *Asia Pac J Public Health*. 2003;15(2):79–87. doi:10.1177/101053950301500202
3. Fatoye F, Gebrye T, Ryan CG, Useh U, Mbada C. Global and regional estimates of clinical and economic burden of low back pain in high-income countries: a systematic review and meta-analysis. *Front Public Health*. 2023;11. doi:10.3389/fpubh.2023.1098100
4. Mohd Isa IL, Teoh SL, Mohd Nor NH, Mokhtar SA. Discogenic low back pain: anatomy, pathophysiology and treatments of intervertebral disc degeneration. *Int J Mol Sci*. 2022;24(1). doi:10.3390/ijms24010208
5. Kirnaz S, Capadona C, Wong T, et al. Fundamentals of intervertebral disc degeneration. *World Neurosurg*. 2022;157:264–273. doi:10.1016/j.wneu.2021.09.066
6. Manchikanti L, Kaye AD, Soin A, et al. Comprehensive evidence-based guidelines for facet joint interventions in the management of chronic spinal pain: American Society of Interventional Pain Physicians (ASIPP) guidelines facet joint interventions 2020 guidelines. *Pain Physician*. 2020;23(3S):S1–S127.
7. Watters WC, Resnick DK, Eck JC, et al. Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 13: injection therapies, low-back pain, and lumbar fusion. *J Neurosurg Spine*. 2014;21(1):79–90. doi:10.3171/2014.4.SPINE14281
8. Ni J, Fang X, Zhong W, Liu N, Wood KB. Anterior lumbar interbody fusion for degenerative discogenic low back pain: evaluation of l4-s1 fusion. *Medicine*. 2015;94(43). doi:10.1097/MD.0000000000001851
9. Lee CK, Shin DA, Kim HI, et al. Automated pressure-controlled discography in patients undergoing anterior lumbar interbody fusion for discogenic back pain. *World Neurosurg*. 2017;97:8–15. doi:10.1016/j.wneu.2016.09.019
10. Jacobs WCH, van der Gaag NA, Kruyt MC, et al. Total disc replacement for chronic discogenic low back pain. *Spine*. 2013;38(1):24–36. doi:10.1097/BRS.0b013e3182741b21
11. Bydon M, De la Garza-Ramos R, Macki M, Baker A, Gokaslan AK, Bydon A. Lumbar fusion versus nonoperative management for treatment of discogenic low back pain: a systematic review and meta-analysis of randomized controlled trials. *J Spinal Disord Tech*. 2014;27(5):297–304. doi:10.1097/BSD.0000000000000072
12. Mannion AF, Brox JI, Fairbank JCT. Comparison of spinal fusion and nonoperative treatment in patients with chronic low back pain: long-term follow-up of three randomized controlled trials. *Spine J*. 2013;13(11):1438–1448. doi:10.1016/j.spinee.2013.06.101
13. Fritzell P, Hägg O, Wessberg P, Nordwall A, Swedish Lumbar Spine Study Group. 2001 volvo award winner in clinical studies: lumbar fusion versus nonsurgical treatment for chronic low back pain: a multicenter randomized controlled trial from the swedish lumbar spine study group. *Spine*. 2001;26(23):2521–2532. doi:10.1097/00007632-200112010-00002
14. Zhang H, Wang Z, Wang Y, et al. Biomaterials for interbody fusion in bone tissue engineering. *Front Bioeng Biotechnol*. 2022;10. doi:10.3389/fbioe.2022.900992
15. Scott-Young M, Nielsen D, Riar S. Fundamentals of mechanobiology and potential applications in spinal fusion. *Int J Spine Surg*. 2023;17(S3):S61–S74. doi:10.14444/8562
16. Seaman S, Kerezoudis P, Bydon M, Torner JC, Hitchon PW. Titanium vs. polyetheretherketone (PEEK) interbody fusion: meta-analysis and literature review. *J Clin Neurosci*. 2017;44:23–29. doi:10.1016/j.jocn.2017.06.062
17. Rathbone J, Rackham M, Nielsen D, et al. A systematic review of anterior lumbar interbody fusion (ALIF) versus posterior lumbar interbody fusion (PLIF), transforaminal lumbar interbody fusion (TLIF), posterolateral lumbar fusion (PLF). *Eur Spine J*. 2023;32(6):1911–1926. doi:10.1007/s00586-023-07567-x
18. Giannoudis PV, Einhorn TA, Marsh D. Fracture healing: the diamond concept. *Injury*. 2007;38(Suppl 4):S3–S6. doi:10.1016/S0020-1383(08)70003-2
19. Malham GM, Parker RM, Ellis NJ, et al. Anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2: a prospective study of complications. *J Neurosurg Spine*. 2014;21(6). doi:10.3171/2014.8
20. Faundez A, Tournier C, Garcia M, et al. Bone morphogenetic protein use in spine surgery-complications and outcomes: a systematic review. *Int Orthop*. 2016;40(6):1309–1319. doi:10.1007/s00264-016-3149-8
21. Walker B, Koerner J, Sankarayanaryanan S, Radcliff K. A consensus statement regarding the utilization of BMP in spine surgery. *Curr Rev Musculoskelet Med*. 2014;7(3):208–219. doi:10.1007/s12178-014-9224-0
22. Simmonds MC, Brown JVE, Heirs MK, et al. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. *Ann Intern Med*. 2013;158(12):877–889. doi:10.7326/0003-4819-158-12-201306180-00005
23. Fu R, Selph S, McDonagh M, et al. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. *Ann Intern Med*. 2013;158(12):890–902. doi:10.7326/0003-4819-158-12-201306180-00006
24. Burkus JK, Gornet MF, Schuler TC, Kleeman TJ, Zdeblick TA. Six-year outcomes of anterior lumbar interbody arthrodesis with use of interbody fusion cages and recombinant

human bone morphogenetic protein-2. *J Bone Joint Surg Am Vol.* 2009;91(5):1181–1189. doi:10.2106/JBJS.G.01485

25. D'Souza M, Macdonald NA, Gendreau JL, Duddlestone PJ, Feng AY, Ho AL. Graft materials and biologics for spinal interbody fusion. *Biomedicine.* 2019;7(4). doi:10.3390/biomedicine7040075

26. Wang J, Lü D, Mao D, Long M. Mechanomics: an emerging field between biology and biomechanics. *Protein Cell.* 2014;5(7):518–531. doi:10.1007/s13238-014-0057-9

27. McCormick JD, Werner BC, Shimer AL. Patient-reported outcome measures in spine surgery. *J Am Acad Orthop Surg.* 2013;21(2):99–107.

28. Beighley A, Zhang A, Huang B, et al. Patient-reported outcome measures in spine surgery: a systematic review. *J Craniovertebr Junction Spine.* 2022;13(4):378–389. doi:10.4103/jcvjs.jcvjs\_101\_22

29. Lehr AM, Duits AAA, Reijnders MRL, et al. Assessment of posterolateral lumbar fusion: a systematic review of imaging-based fusion criteria. *JBJS Rev.* 2022;10(10). doi:10.2106/JBJS.RVW.22.00129

30. Choudhri TF, Mummaneni PV, Dhall SS, et al. Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 4: radiographic assessment of fusion status. *SPI.* 2014;21(1):23–30. doi:10.3171/2014.4.SPINE14267

31. Parker SL, Adogwa O, Mendenhall SK, et al. Determination of minimum clinically important difference (MCID) in pain, disability, and quality of life after revision fusion for symptomatic pseudoarthrosis. *Spine J.* 2012;12(12):1122–1128. doi:10.1016/j.spinee.2012.10.006

32. Parker SL, Mendenhall SK, Shau D, et al. Determination of minimum clinically important difference in pain, disability, and quality of life after extension of fusion for adjacent-segment disease. *SPI.* 2012;16(1):61–67. doi:10.3171/2011.8.SPINE1194

33. Copay AG, Glassman SD, Subach BR, Berven S, Schuler TC, Carreon LY. Minimum clinically important difference in lumbar spine surgery patients: a choice of methods using the Oswestry Disability Index, medical outcomes study questionnaire short form 36, and pain scales. *Spine J.* 2008;8(6):968–974. doi:10.1016/j.spinee.2007.11.006

34. Issa TZ, Lee Y, Henry TW, et al. Values derived from patient reported outcomes in spine surgery: a systematic review of the minimal clinically important difference, substantial clinical benefit, and patient acceptable symptom state. *Eur Spine J.* 2023;32(10):3333–3351. doi:10.1007/s00586-023-07896-x

35. Chen SH, Tai CL, Lin CY, et al. Biomechanical comparison of a new stand-alone anterior lumbar interbody fusion cage with established fixation techniques – a three-dimensional finite element analysis. *BMC Musculoskelet Disord.* 2008;9. doi:10.1186/1471-2474-9-88

36. Cain CMJ, Schleicher P, Gerlach R, Pflugmacher R, Scholz M, Kandziora F. A new stand-alone anterior lumbar interbody fusion device: biomechanical comparison with established fixation techniques. *Spine.* 2005;30(23):2631–2636. doi:10.1097/01.brs.0000187897.25889.54

37. Guyer RD, Zigler JE, Blumenthal SL, Shellock JL, Ohnmeiss DD. Evaluation of anterior lumbar interbody fusion

performed using a stand-alone, integrated fusion cage. *Int J Spine Surg.* 2023;17(1):1–5. doi:10.14444/8354

38. Fujii K, Yamazaki M, Kang JD, et al. Discogenic back pain: literature review of definition, diagnosis, and treatment. *JBMR Plus.* 2019;3(5). doi:10.1002/jbm4.10180

39. Scott-Young MN, Grosser DM, Zotti MGT. Anterior lumbar spinal reconstruction. *Handb of Spine Technol Springer.* 2021:1165–1207. doi:10.1007/978-3-319-44424-6\_124

40. Holt RT, Majd ME, Vadhva M, Castro FP. The efficacy of anterior spine exposure by an orthopedic surgeon. *J Spinal Disord Tech.* 2003;16(5):477–486. doi:10.1097/00024720-200310000-00007

41. Burkus JK, Transfeldt EE, Kitchel SH, Watkins RG, Balderston RA. Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. *Spine.* 2002;27(21):2396–2408. doi:10.1097/00007632-200211010-00015

42. Mobbs RJ, Phan K, Assem Y, Pelletier M, Walsh WR. Combination ti/PEEK ALIF cage for anterior lumbar interbody fusion: early clinical and radiological results. *J Clin Neurosci.* 2016;34:94–99. doi:10.1016/j.jocn.2016.05.028

43. Ni J, Zheng Y, Liu N, et al. Radiological evaluation of anterior lumbar fusion using PEEK cages with adjacent vertebral autograft in spinal deformity long fusion surgeries. *Eur Spine J.* 2015;24(4):791–799. doi:10.1007/s00586-014-3745-5

**Funding:** The authors received no financial support for the research, authorship, and/or publication of this article.

**Declaration of Conflicting Interests:** The authors report no conflicts of interest in this work.

**Disclosures:** This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The authors have no conflicts of interest to disclose.

**Ethics approval:** This study was approved by the University Human Research Ethics Committee (0000015881) of Bond University.

**Corresponding Author:** Matthew Scott-Young, Faculty of Health Science & Medicine, Bond University, 27 Garden Street, Southport, Gold Coast, QLD 4215, Australia; swalter@goldcoastspine.com.au

Published 05 November 2024

This manuscript is generously published free of charge by ISASS, the International Society for the Advancement of Spine Surgery. Copyright © 2024 ISASS. To see more or order reprints or permissions, see <http://ijssurgery.com>.